Cardlytics(US:CDLX) GlobeNewswire News Roomยท2024-08-15 20:00Core Viewpoint - Cardlytics, Inc. has faced significant scrutiny following a substantial miss in its Q2 2024 financial results, attributed to known technology issues that have persisted for at least one to two quarters [2]. Investigation Details - Cardlytics previously claimed that its technology initiatives were yielding positive results, but the recent financial report contradicted this assertion [2]. - The company reported a significant shortfall in its financial projections from three months prior, leading to a decline in stock value [2]. - Management acknowledged that the technology issues had been recognized internally for a quarter or two before the public disclosure [2]. Next Steps - Investors who have information related to the investigation or who purchased Cardlytics securities are encouraged to participate in the investigation [3]. Legal Representation - Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful in their legal actions [4]. - The firm has a history of representing investors in securities fraud class actions and has recovered hundreds of millions of dollars for clients [5].